{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:15:55Z","timestamp":1783455355085,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jid.2024.08.034","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:15:38Z","timestamp":1727810138000},"page":"1070-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-5271","authenticated-orcid":false,"given":"Maria C.","family":"Schneeweiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-8996","authenticated-orcid":false,"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6832-5900","authenticated-orcid":false,"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-4100","authenticated-orcid":false,"given":"Priyanka","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-3106","authenticated-orcid":false,"given":"Yinzhu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7433-1826","authenticated-orcid":false,"given":"Joan","family":"Landon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-0708","authenticated-orcid":false,"given":"David M.","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-4800","authenticated-orcid":false,"given":"Robert","family":"Sidbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-467X","authenticated-orcid":false,"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.08.034_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/bjd.18296","article-title":"Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A","volume":"182","author":"Andersen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib2","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/sim.3150","article-title":"A\u00a0critical appraisal of propensity-score matching in the medical literature between 1996 and 2003","volume":"27","author":"Austin","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2024.08.034_bib3","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2024.08.034_bib4","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The vaccine safety datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jid.2024.08.034_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","article-title":"Good Practices for Real-World Data Studies of Treatment and\/or Comparative Effectiveness: recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making","volume":"20","author":"Berger","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jid.2024.08.034_bib6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2024.08.034_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A\u00a0systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, Brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.08.034_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/aje\/kwg115","article-title":"Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders","volume":"158","author":"Cepeda","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jid.2024.08.034_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamadermatol.2016.4129","article-title":"Diversity in dermatology clinical trials: a systematic review","volume":"153","author":"Charrow","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pds.1554","article-title":"Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores","volume":"17","author":"Eng","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2024.08.034_bib12","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.08.034_bib13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/cpt.1633","article-title":"Nonrandomized real-world evidence to support regulatory decision Making: process for a randomized trial replication project","volume":"107","author":"Franklin","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2024.08.034_bib14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2024.08.034_bib15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jval.2013.05.008","article-title":"Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research","volume":"16","author":"Gagne","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jid.2024.08.034_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A\u00a0combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jid.2024.08.034_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib18","first-page":"252","article-title":"Propensity scores in pharmacoepidemiology","volume":"98","author":"Glynn","year":"2006","journal-title":"Basic Clin Phar Tox"},{"key":"10.1016\/j.jid.2024.08.034_bib19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death\u00a0and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2024.08.034_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMe1906559","article-title":"New guidelines for statistical reporting in the journal","volume":"381","author":"Harrington","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.08.034_bib21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"key":"10.1016\/j.jid.2024.08.034_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00403-022-02435-y","article-title":"Assessment of the validity of international classification of disease tenth revision codes for atopic dermatitis","volume":"315","author":"Iyer","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2024.08.034_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib24","series-title":"Methods in observational epidemiology","author":"Kelsey","year":"1996"},{"key":"10.1016\/j.jid.2024.08.034_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/09546634.2017.1373736","article-title":"New and emerging targeted systemic therapies: a new era for atopic dermatitis","volume":"29","author":"Lee","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.08.034_bib26","first-page":"5","article-title":"Emerging therapies in psoriasis: a systematic review","volume":"101","author":"Lee","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.jid.2024.08.034_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema","volume":"60","author":"Lewis-Jones","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jid.2024.08.034_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000478072","article-title":"Adverse reactions to biologics in psoriasis","volume":"53","author":"Lockwood","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib29","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic treatment of adult atopic dermatitis: a review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2024.08.034_bib31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jval.2020.04.002","article-title":"Improving Transparency to Build Trust in Real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative","volume":"23","author":"Orsini","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jid.2024.08.034_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.08.034_bib33","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/dom.13735","article-title":"Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: a sequential monitoring programme in routine care","volume":"21","author":"Patorno","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jid.2024.08.034_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.103","article-title":"The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: design and exposure accrual for an evaluation of empagliflozin in routine clinical care","volume":"3","author":"Patorno","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jid.2024.08.034_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.clindermatol.2018.05.005","article-title":"Bacterial colonization, overgrowth, and superinfection in atopic dermatitis","volume":"36","author":"Rangel","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2024.08.034_bib37","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jid.2024.08.034_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2019.10.005","article-title":"New treatments for atopic dermatitis targeting beyond IL-4\/IL-13 cytokines","volume":"124","author":"Renert-Yuval","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jid.2024.08.034_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.2311","article-title":"The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety","volume":"21","author":"Robb","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2024.08.034_bib40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis","volume":"79","author":"R\u00f8nnstad","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.jid.2024.08.034_bib42","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","article-title":"Overadjustment bias and unnecessary adjustment in epidemiologic studies","volume":"20","author":"Schisterman","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.jid.2024.08.034_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.08.034_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","article-title":"Developments in post-marketing comparative effectiveness research","volume":"82","author":"Schneeweiss","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2024.08.034_bib45","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A\u00a0basic study design for expedited safety signal evaluation based on electronic healthcare data","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2024.08.034_bib46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/clpt.2011.235","article-title":"Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development","volume":"90","author":"Schneeweiss","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2024.08.034_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005173","article-title":"Sequential monitoring of the comparative effectiveness and safety of dabigatran in routine care","volume":"12","author":"Schneeweiss","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jid.2024.08.034_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100226","article-title":"Concepts of designing and implementing pharmacoepidemiology studies on the safety of systemic treatments in dermatology practice","volume":"3","author":"Schneeweiss","year":"2023","journal-title":"JID Innov"},{"key":"10.1016\/j.jid.2024.08.034_bib49","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s12325-017-0582-z","article-title":"Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, medicare, and Medi-Cal databases","volume":"34","author":"Shrestha","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jid.2024.08.034_bib50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.08.034_bib51","first-page":"2021","volume":"Q3","year":"2020"},{"key":"10.1016\/j.jid.2024.08.034_bib52","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study","volume":"172","author":"St\u00fcrmer","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jid.2024.08.034_bib53","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jdv.13150","article-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of Psoriasis and Psoriatic Arthritis survey","volume":"29","author":"van de Kerkhof","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.08.034_bib54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pds.4295","article-title":"Reporting to improve reproducibility and facilitate validity assessment for\u00a0healthcare database studies","volume":"26","author":"Wang","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jid.2024.08.034_bib55","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2024.08.034_bib56","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1038\/s41467-022-32310-3","article-title":"Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.08.034_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"10.1016\/j.jid.2024.08.034_bib58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2024.08.034_bib59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/oxfordjournals.aje.a117563","article-title":"Recall accuracy for prescription medications: self-report compared with database information","volume":"142","author":"West","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jid.2024.08.034_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0895-4356(94)90021-3","article-title":"Completeness of prescription recording in outpatient medical records from a health maintenance organization","volume":"47","author":"West","year":"1994","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jid.2024.08.034_bib61","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2020.06.051","article-title":"Navigating immunosuppression in a pandemic: a guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists","volume":"83","author":"Zahedi Niaki","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24021699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24021699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:01:00Z","timestamp":1777633260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24021699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0022202X24021699"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.08.034","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}